cells requiring to be eliminated, and, when measured late in using the polymerase chain reaction (PCR) is strongly predicthe disease, the level of MRD may provide evidence for tive of outcome in childhood acute lymphoblastic leukemia impending relapse. MRD can be detected in a proportion of intermediate for levels between 10 −3 and 2 × 10 −5 ; and the
the disease, the level of MRD may provide evidence for tive of outcome in childhood acute lymphoblastic leukemia impending relapse. MRD can be detected in a proportion of relation between high levels of disease at the end of induction and subsequent poor outcome.
3-6
Quantification of MRD is complex and time consuming and Introduction at the present time is not feasible as a technique for the routine laboratory. If a level of MRD Ͼ10 −3 is truly a strong predictor Approximately 25% of children with acute lymphoblastic leuof a poor outcome, then a simple technique for detecting kemia and a substantially higher proportion of adults relapse patients with a high level of MRD could well be of clinical after conventional treatment for their disease. Early detection value, provided that effective treatment were available for of patients likely to relapse could lead to alteration of treatthose patients. Monoclonal gene rearrangements can be ment and a consequent decrease in the probability of relapse.
detected by Southern blotting and Katz et al 7 reported that In a proportion of patients, it is possible to identify factors, patients in whom MRD could be detected by this means at such as translocations or a high white cell count, which indithe end of induction had a poor prognosis. However, mixing cate a poor prognosis but, except for the presence of the 9;22 experiments suggest that Southern blotting has a sensitivity of translocation, most factors indicating a poor prognosis are only 1-2 × 10 −2 . Monoclonal gene rearrangements can also imprecise and a poor guide to treatment. In childhood leukebe detected by PCR using consensus primers which span the mia most relapses still occur in patients in whom factors precomplementarity determining region (CDR)3 or CDR2/3 dicting a poor prognosis cannot be identified.
region. As the monoclonal signal is seen against a background Detection and measurement of minimal residual disease signal derived from normal polyclonal lymphocytes, the sensi-(MRD) is an attractive candidate for predicting outcome.
tivity of monoclonality for detection of a leukemic population When measured early in disease, the level of MRD provides depends on the number of background normal lymphocytes. 10 at a level of 6 × 10 −4 when measured against a back-ground of normal marrow cells. These levels of sensitivity are CTGCAGGC(C/T)(C/T)CCGG(A/G)AA(A/G)(A/G)GTCTGGAG-TGG 3′. probably comparable given the relative proportions of lymphocytes in blood and marrow.
A single round multiplex PCR as previously described 9 was used to detect the rearranged TCR␥ gene except that an In view of the paucity of in vitro data, the lack of in vivo data, and the possibility that detection of monoclonality may annealing temperature of 63°C and a denaturing temperature of 91°C were used. The PCR was performed in duplicate for be able to detect leukemia down to a level of 10
, we evaluated the sensitivity and specificity of detection of monoall samples and DNA extraction solutions and PCR buffers were used as negative controls. PCR products were separated clonality in a series of marrow specimens from children with ALL during induction therapy. The MRD value, as determined on 6% polyacrylamide gels and then stained with 0.3 g/ml ethidium bromide prior to visualisation under UV light. by PCR with patient-specific primers and limiting dilution quantification, was used as the reference value.
Samples were scored as monoclonal (M) at diagnosis if one or more distinct PCR bands were observed in both duplicates in the presence or absence of any polyclonal background, with the bands observed being the same in each duplicate.
Materials and methods
Samples were scored as polyclonal (P) if only polyclonal PCR product was observed. The same criteria were used for marPatient samples row aspirates taken during induction, with the additional criterion that the monoclonal band(s) detected had to be of the Forty-six consecutive ALL patients enrolled in the Australian same molecular weight as that detected at diagnosis. and New Zealand Children's Cancer Study Group, Study VI, treated at the Women's and Children's Hospital, Adelaide were studied. The cell lineage of the leukemia was determined Quantification by immunophenotyping. Patients had induction therapy of vincristine, prednisolone, daunorubicin, and asparaginase and MRD was quantified using the limiting dilution analysis subsequent therapy involving CNS prophylaxis, consolidation method of Sykes et al. 15 Briefly, the CDR3 region of the IgH and maintenance.
gene from the leukemic cells was amplified from bone marMaterial from bone marrow aspirates at diagnosis was studrow at diagnosis and DNA sequenced using the method ied in all 46 patients, at day 14 of induction therapy in 31 described in Ralph et al. 16 A pair of patient-specific PCR pripatients, at day 21 in 18 patients and at the end of induction mers were then designed to the CDR2 and/or CDR3 regions, therapy, termed for simplicity as day 35, in 31 patients.
to yield a highly specific and sensitive test for the leukemic These studies were approved by both the Women's and clone. Where multiple monoclonal IgH bands were detected Children's Hospital and the Flinders Medical Centre Ethics at diagnosis, only one of the bands (usually the longest PCR committees.
product) was sequenced and quantified. The total number of amplifiable genomes in a sample was measured as the number of amplifiable molecules of the endogenous N-ras gene. 15 Ser-DNA extraction ial dilutions with multiple replicate samples were used to quantify the leukemic and N-ras marker using Poisson stat-DNA extraction was performed either by proteinase K digesistics for analysis. 17 MRD levels were expressed as the ratio tion and phenol extraction using standard methods, or by of leukemic cells to normal cells, assuming one leukemic Instagene (Biorad, Richmond, CA, USA) according to the rearrangement and two N-ras genes/cell. manufacturer's instructions.
Quantification was performed twice for five of 21 day 14 samples, four of 12 day 21 samples and for 26 of 31 day 35 samples. If two quantifications were performed on a sample Detection of IgH and TCR␥ monoclonality then the level of MRD given is the geometric mean of the two. Replicate estimation of MRD in 22 leukemic samples in which disease was detected and quantified in both replicates has The PCR protocols used for detection of IgH and TCR␥ gene rearrangements were similar to those published previously 9 shown that the 95% confidence limit for a single estimate is equivalent to multiplication or division of the observed value but with the following modifications.
The IgH gene rearrangement was amplified in a semi-nested by a factor of 4.9 (Brisco et al, unpublished data) . Sequences of IgH genes, and the primers used for quantifitwo-round hot-start PCR 11 using consensus primers. 12, 13 Approximately 100-200 ng of genomic DNA was added to cation are available from Genbank 18 (Accession Numbers L76949-L76971; L77663-L77668; L77972; L77982). the first round PCR mix. The first round of PCR involved 30 cycles of 60°C annealing for 1 min, 72°C for 1 min and 94°C for 1 min with primers FR3A 5′ACACGGC(C/T)-(G/C)TGTATTACTGT 3′ and LJH 5′TGAGGAGACGGTGACC-Results 3′. A 10 −3 final dilution of the first round product was added to the second round reaction mix and amplified by 20 more Samples cycles of the above cycling conditions using primers FR3A and VLJH 5′GTGACCAGGGT(A/G/C/T)CCTTGGCCCCAG 3′.
Forty-six patients were studied for monoclonality at diagnosis. There were six T lineage ALL patients: they all exhibited one Both PCR rounds were performed in a 25 l reaction containing 67 mm Tris HCl pH 8.8, 16.6 mm (NH 4 ) 2 SO 4 , 0.45% (v/v) or more TCR␥ rearrangements but were not studied further.
Of the remaining 40 B lineage ALL patients, 38 showed one Triton X-100, 200 g/ml gelatin, 2 mm MgCl 2 , 100 m of each dNTP and 0.2U Taq (Bresatec, Adelaide, Australia). If patients or more monoclonal IgH and/or TCR␥ rearrangements and quantification was successful in 31 of them at diagnosis and gave no amplified product with primer FR3A, then it was replaced by a framework 2 primer, 14 FR2B 5′GTC-at various times during induction.
Figure 1
Detection of IgH monoclonality in bone marrow aspirate DNA samples at diagnosis and during induction therapy. Samples were amplified using PCR and the IgH PCR product analyzed by electrophoresis on 6% polyacrylamide gels. Samples for two patients are shown at diagnosis (d 0) and for days 14 and 35 (d 14, d 35) of induction therapy. Patient 1 had two IgH monoclonal PCR bands at diagnosis and persistent IgH PCR bands of the same molecular weights as observed at diagnosis were detected throughout induction. Patient 2 possessed an IgH monoclonal band at diagnosis which was detected at day 14 but not at day 35 during induction. Mk, pUC19/HpaII molecular weight standards with sizes in base pairs shown at the side of the figure; −, negative PCR control. P and M are control samples known to be polyclonal and monoclonal, respectively. Monoclonality TCR␥ locus: no persistent monoclonal population could be detected. For the 25 patients showing TCR␥ rearrangement at diagnosis a monoclonal band was detected at the TCR␥ locus Of the 40 B lineage ALL patients, 37 (93%) exhibited one or more monoclonal IgH rearrangements and one did not exhibit in 4/21 (19%) patients on day 14, 2/10 (20%) patients on day 21 and 2/25 (8%) patients on day 35. In one patient (No. 507) an IgH rearrangement but did exhibit a TCR␥ rearrangement. Fifteen of 37 (41%) of the B lineage ALL patients gave multiple the day 35 sample was scored as M (faint band) in one experiment and P in a second experiment, but was scored as monomonoclonal bands at the IgH locus (10 with two bands, three with three bands and two with four bands). Twenty-four of 37 clonal. In general, monoclonality was detected during the earlier induction samples and then the samples became poly-(65%) patients exhibited monoclonal bands at both the IgH and TCR␥ loci at diagnosis. Multiple monoclonal bands were clonal (see Figures 1 and 2 ). Only in one case was a monoclonal band detected at day 35 but not on earlier samples and not detected at the TCR␥ locus in B-ALL patients. Figure 1 shows representative results from two patients studthis was in patient 507 mentioned above. In all but two cases where monoclonality was detected during induction, the ied at the IgH locus: patient 1 shows a persistent monoclonal population throughout induction, whereas patient 2 shows a number of monoclonal bands present was the same as at diagnosis. In one patient, two of the four bands detected at diagpersistent population only on day 14. For the 37 patients showing IgH rearrangements at diagnosis, a monoclonal nosis were still present at days 14 and 35. In the other patient only one of the original three bands was still present at day rearrangement of the same molecular weight as that detected at diagnosis was observed in 12/30 (40%) patients on day 14, 35, and a new band had emerged. There were 24 patients who exhibited both IgH and TCR␥ 5/17 (29%) patients on day 21, and 11/37 (30%) patients on day 35. Figure 2 shows results from patient 1 studied at the rearrangements at diagnosis. The monoclonality results for these patients at different days during induction are given in Table 1 . On day 35 samples there was a significantly (P = 0.023, Fishers exact test, two-tailed) greater frequency of detection of IgH monoclonal than TCR␥ monoclonal bands, suggesting that the IgH gene provided greater sensitivity than the TCR␥ gene for detection of the leukemic rearrangement. This is illustrated by patient 1, in whom a persistent mono- Monoclonality (᭹) or polyclonality (᭺) in relation to level of disease during induction therapy. The detection of monoclonality at diagnosis was a criterion for entry into the study. Levels of MRD refer either to samples in which disease could be detected and definitively quantified (+) or samples in which disease could not be detected and therefore only an upper level could be established (−).
clonal population throughout induction was detected by IgH
The results for day 35 samples alone are given in Table 3 . For these samples the sensitivity was 100% (7/7) and the (Figure 1 ), but not by TCR␥ (Figure 2) . specificity was 88% (21/24), the positive predictive value was 0.7 (7/10) and the negative predictive value was 1.0 (21/21) . Of the 10 patients exhibiting a monoclonal band at day 35, Sensitive quantification seven had MRD levels ranging from 1.7 × 10 −1 to 2.1 × 10 −3 . Where monoclonality was not detected at the end of inducOf the 37 patients in whom an IgH rearrangement was tion, the level of MRD ranged from 5.9 × 10 −4 to 1.4 × 10 −6
. detected at diagnosis, MRD was subsequently quantified durOne patient (480) who exhibited a monoclonal band had a ing induction in 31. Sequencing or design of patient-specific level of disease of 6 × 10
, which was very close to the 10 −3 primers was unsuccessful for five patients and samples were cut off. There were two patients who had low levels of disease not available during induction for quantification for one (2.6 × 10 −5 and 2.4 × 10
) at day 35 and in whom a monopatient. Exact quantification was possible for 84 of the 95 clonal band was detected. In one patient (497), the band at samples studied from the 31 patients but only upper estimates day 35 was sequenced and found not to be the same as that of MRD level could be established for the remaining 11 observed at diagnosis. The day 35 sequence was 3 base pairs samples owing to lack of sufficient material for study. These longer than that at diagnosis, a size difference which would were all polyclonal by the monoclonality test and had levels not easily be detected on a 6% polyacrylamide gel. In the of disease Ͻ5.9 × 10 −4 . other patient (507), the monoclonal band was very faint and The relationship between detection of monoclonality and was only observed in one of two experiments. the level of MRD is shown in Figure 3 and is summarized in Table 2 for a cut-off point of MRD у10 −3 for samples taken during days 14-35. The sensitivity of detection of a level of Discussion MRD of у10 −3 by detection of monoclonality was 78% (18/23) and the specificity of detection was 93% (38/41). The
The aim of this study was to determine the sensitivity, specipositive predictive value of monoclonality detection was 0.86 ficity and predictive value that detection of a monoclonal (18/21) and the negative predictive value was 0.88 (38/43).
gene rearrangement has for indicating levels of MRD greater or less than 10 −3 during induction therapy in ALL. The sensi- Table 2 Detection of IgH monoclonality and sensitive quantifi- tivity with which a monoclonal gene rearrangement can be inherent difference in sensitivity of the two amplification systems; more rapid recovery during induction of normal polydetected depends upon the relative strength of the signal from the amplified gene rearrangement derived from the leukemic clonal T lymphocytes than of B lymphocytes; or contamination of the aspirate by peripheral blood lymphocytes, which clone as compared to the noise of the amplified gene rearrangements derived from normal polyclonal lymphocytes.
are predominantly T lymphocytes. We previously studied monoclonality and sensitivity detecThis signal to noise ratio will therefore depend upon the absolute number of leukemic cells present, the absolute number of tion using archival material extracted from marrow smears on microscope slides. This resulted in DNA which was limited in B or T lymphocytes present in the marrow and on the extent of admixture of peripheral blood lymphocytes which occurs both quality and quantity. Using this DNA the monoclonality test was of some but limited prognostic value when compared during marrow aspiration. PCR amplification of gene rearrangements for detection of monoclonality is based upon with sensitive quantification studies. 2, 19 The present study used DNA from fresh samples with further optimized PCR the use of consensus primers which may bind to and/or extend from different rearrangements with different efficiencies, and conditions and larger DNA samples. In the present study we detected a monoclonal band at day 35 in 35% of samples an additional source of variability is the relative efficiency of amplification of the leukemic and the various normal compared with only 20% in our archival studies but it is too soon to determine the value of detection of monoclonality or rearrangements. These factors may vary from patient to patient and depend on the stage of treatment, and may therefore sensitive quantification in the present study for prognostication of subsequent clinical outcome. result in some variability in the efficiency of detection of monoclonality at a given level of MRD.
Detection of monoclonality has the advantages of simplicity and low cost. It has the additional advantage of being quick, Of the 23 samples which had MRD у10 −3
, 18 also had a monoclonal band giving a sensitivity of 78%, and only 3/41 which potentially allows early decision as to change of treatment. It has the disadvantages of being non-quantitative and samples which had an MRD level Ͻ10 −3 were detected by monoclonality, giving a specificity of 93%. The positive and somewhat variable. Both sensitive quantification and monoclonality detection can be affected by clonal selection and negative predictive values for the monoclonality test were 0.86 and 0.88, respectively.
evolution. However, in some cases of evolution, monoclonality will enable detection of a new clone whereas sensiThere were five false-negative samples which had a level of MRD у10 −3 and were polyclonal. The level of disease tive quantification will not. One could envisage that detection of monoclonality could ranged from 1-4 × 10 −3 and was very close to the 10 −3 cutoff for the detection of monoclonality. There were three falsebe used in two ways for management of leukemia. Detection of monoclonality early in treatment, such as at the end of positive samples (patient Nos 480, 497 and 507), all on day 35, in which monoclonality was detected and yet the measinduction, could identify patients who have relatively high levels of disease and are at high risk of relapse; such patients ured levels of MRD were Ͻ10 −3
. Patient 507 had a low level of disease quantified at day 35; in one experiment a clearly might benefit by more intensive or different treatment. Detection of monoclonality later during the course of treatment polyclonal result was observed whereas in a second experiment a weak monoclonal band was scored by two observers. might be able to identify patients who were relapsing, particularly if monoclonality had not been present in an earlier This patient was a typical example of the problem associated with scoring detection of a faint monoclonal band against a specimen. However, clonal evolution, which occurs frequently during treatment, [20] [21] [22] [23] could confound the use of polyclonal background. In patient 497 there were four monoclonal bands at diagnosis, two of which were present at day detection of monoclonality if it resulted in replacement of a well amplified gene rearrangement by a poorly amplified one. 35. One of the bands detected in the day 35 sample appeared to be of the same molecular weight as that which had been sequenced from the diagnostic sample and from which the patient-specific primers were designed. However, sequencingwhether or not a band observed during induction was the The TCR␥ PCR system appeared to be less sensitive than the lar quantification of residual disease at the end of induction. LanIgH PCR system at detecting MRD during induction (Table 1) 
